Latest Conference Articles

Report One, reportedly the first agentic reporting tool specifically geared to breast imaging, is one of three new products that will be showcased by MagView at the upcoming RSNA conference.

Artificial intelligence plaque analysis of CCTA scans showed that 27 percent of former NFL players had severe or extensive total plaque volume, according to a new study to be presented at the American Heart Association Scientific Sessions 2026 this week.

New research suggests CCTA may provide salient preoperative insights into planning for percutaneous coronary intervention (PCI) while facilitating similar outcomes as intravascular ultrasound guidance for target-vessel failure.

In a recent interview with Diagnostic Imaging, Eliad Josephson discussed key attributes of the HLTH USA conference, AI trends and an ongoing shift of emphasis on the development of predictive technologies with diagnostics at center stage.

In a recent interview, Phillip Koo, MD, discussed emerging trends with AI, theranostics and empowered patients, and how these developments may lead to challenges and potential opportunities for radiologists and nuclear medicine physicians.

How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.

In the third of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss recent developments with autonomous AI in breast imaging and share their perspective on the overall potential of AI to help mitigate the radiologist shortage.

In a recent interview, Amir Iravani, MD, FRACP, discussed the radiotherapeutic agent 177Lu-edotreotide and new dosimetry data from the COMPETE trial that was recently presented at the ASTRO conference.

In the second of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss how to handle disagreements with adjunctive AI in breast imaging, whether to include AI assessments in PACS, and whether patients should pay for the use of adjunctive AI.

For patients with small cell lung cancer (SCLC), there was a 40 percent improvement in cognitive failure-free survival (CFFS) with brain MRI alone in comparison to the combination of brain MRI and prophylactic cranial irradiation (PCI), according to research presented at the ASTRO conference.

In the second of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss challenges with evaluating value and ROI for AI software, the physician time required to do so, and possible solutions to facilitate improved clarity and consistency with AI reimbursement.

In the first of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss current challenges with reimbursement for AI in radiology.

Catch up on the latest imaging research from the recent European Society of Cardiology (ESC) Congress.

Elevated coronary inflammation, measured with the CCTA-derived and AI-enabled perivascular fat attenuation index (FAI) score, was associated with over a 12-fold higher risk for cardiovascular mortality in patients with no diabetes, hypertension, smoking history or obesity, according to new research presented at the European Society of Cardiology (ESC) Congress.

New research presented at the European Society of Cardiology (ESC) conference demonstrates that fractional flow reserve (FFR) based off CCTA exams significantly decreases unnecessary invasive coronary angiography (ICA) procedures for patients with stable chest pain and obstructive stenosis.

In a recent interview, Kenneth Chan, MBBS, discussed new research, presented at the recent Society of Cardiovascular Computed Tomography (SCCT) conference, that showed the impact of coronary inflammation in identifying elevated cardiovascular risk in patients with zero or low coronary artery calcium (CAC) scores.

Catch up on the latest imaging research from the recent Society of Cardiovascular Computed Tomography (SCCT) conference.

In an address at the recent SNMMI conference, neuroradiologist Tammie Benzinger, MD, PhD, discussed key studies in the evolution of amyloid and tau PET, and their continued emergence in detection, staging and monitoring of people with dementia.

In a recent interview, Ron Blankstein, MD, discussed new research presented at the Society of Cardiovascular Computed Tomography (SCCT) conference, including a study examining the impact of notification of AI detection of coronary plaque on physicians prescribing lipid-lowering therapy.

Out of multiple potential risk factors for the development of preeclampsia, ranging from hypertension to non-gestational diabetes and maternal age > 35, researchers found that pre-pregnancy coronary artery calcium (CAC) was the only risk factor significantly associated with preeclampsia.

For patients having CT angiography prior to TAVR procedures, researchers found that photon-counting detector CT (PCD-CT) offered higher specificity and PPV for detecting significant coronary artery disease (CAD), according to study findings to be presented at the Society of Cardiovascular Computed Tomography (SCCT) conference.

For patients with known or suspected neuroendocrine tumors, the radiopharmaceutical 64Cu-SARTATE offered over 50 percent higher average detection of liver foci than 68Ga-DOTATATE at four hours and 20 hours post-injection, according to research presented at the recent SNMMI conference.

In recent interviews with Diagnostic Imaging, Jeremie Calais, MD, PhD, Michael Hofman, MBBS, FRACP, Heather Jacene, MD, Phillip Kuo, MD, and more shared their thoughts about the potential impact of theranostics and what excites them about the future of nuclear medicine.

Catch up on recent interviews with Michael Hofman, MBBS, FRACP, Heather Jacene, MD, Phillip Kuo, MD, and more discussing new research and advances presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 conference.

In a recent interview discussing the SNMMI conference, Jeremie Calais, MD, PhD, shared his thoughts on emerging advances. a key mentor in nuclear medicine and combination therapy for prostate cancer.

In a recent episode of our “Molecular Imaging in Focus” series, Surekha Yadav, MBBS, MD, discussed research presented at the SNMMI conference that showed significant advantages of PSMA PET over conventional imaging for detection of osseous oligometastatic prostate cancer (PCa).

For patients with advanced melanoma, the melanin-targeted PET radiotracer (¹⁸F)DMPY2 offered superior detection of metastatic foci in the brain and liver in comparison to (¹⁸F)FDG, according to preliminary comparative research presented at the recent SNMMI conference.

Catch up on the latest imaging research from the recent SNMMI conference.